Home › Funds › Nantahala Capital Management, LLC › BCRX

Nantahala Capital Management, LLC position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

Nantahala Capital Management, LLC reported holding 2,101,257 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$17.5M, representing 0.80% of its reported portfolio and ranking #45 among its reported holdings. Nantahala Capital Management, LLC has disclosed BCRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)2.10M sh
Reported value held$17.50M
Portfolio Weight0.80%
First reportedQ4 2025
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Nantahala Capital Management, LLC's BCRX position evolved

Nantahala Capital Management, LLC first disclosed a stake in BCRX in Q4 2025 at 1,356,377 shares (US$10.6M). The position peaked in Q2 2026 at 1,901,160 shares, worth US$19.0M. Across 4 filings, Nantahala Capital Management, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,101,257 shares valued at US$17.5M — an increase of 200,097 shares quarter over quarter.. Notable position changes include a 47% increase in Q1 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.36M $10.58M New
Q1 2026 1.99M $18.92M Add
Q2 2026 1.90M $19.01M Reduce
Q3 2026 2.10M $17.50M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has Nantahala Capital Management, LLC held BCRX?

Nantahala Capital Management, LLC has disclosed BCRX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Nantahala Capital Management, LLC's current position in BCRX?

As of Q3 2026, Nantahala Capital Management, LLC holds 2.10M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $17.50M, representing 0.80% of its reported portfolio and ranking #45.

Has Nantahala Capital Management, LLC been buying or selling BCRX?

In the latest 13F filing (Q3 2026), Nantahala Capital Management, LLC increased its position in BCRX. The position peaked in Q2 2026 at 1.90M shares.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.